Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0D1MA
|
||||
| Former ID |
DAP001124
|
||||
| Drug Name |
Oxyphenonium
|
||||
| Synonyms |
Argicillin; Atrenyl; Hydroxymethylgramicidin; Methacin; Methocidin; Methocidine; Methocidinum; Metocidina; Oxiphenonum; Spastrex;Oxyphenonium Chloride; Oxyphenonium Iodide; Methocidin [DCF:INN]; Methocidine [INN-French]; Methocidinum [INN-Latin]; Metocidina [INN-Spanish]; [2-(2-Cyclohexyl-2-hydroxy-2-phenyl-acetoxy)-ethyl]-diethyl-methyl-ammonium; 2-((Cyclohexylhydroxyphenylacetyl)oxy)-N,N-diethyl-N-methylethanaminium; 2-(2-cyclohexyl-2-hydroxy-2-phenylacetyl)oxyethyl-diethyl-methylazanium; 2-[2-cyclohexyl(hydroxy)phenylacetoxy]-n,n-diethyl-n-methylethanaminium
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Visceral spasms [ICD10:R25.2] | Approved | [1] | ||
| Therapeutic Class |
Parasympatholytics
|
||||
| Company |
Novartis Pharmaceuticals Corp
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C21H34NO3+
|
||||
| InChI |
InChI=1S/C21H34NO3/c1-4-22(3,5-2)16-17-25-20(23)21(24,18-12-8-6-9-13-18)19-14-10-7-11-15-19/h6,8-9,12-13,19,24H,4-5,7,10-11,14-17H2,1-3H3/q+1
|
||||
| InChIKey |
GFRUPHOKLBPHTQ-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 50-10-2
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
6786040, 6805132, 8153527, 10589783, 25687908, 29224786, 46508840, 50064410, 50421464, 57322928, 85209563, 92729657, 103113595, 104171383, 104310145, 105057325, 117579885, 124596745, 124883575, 124883576, 124968859, 127947311, 134338369, 134991339, 135263553, 137148160, 160963567, 164077978, 166265001, 178103831, 179225198, 179418658, 215721396, 226599816
|
||||
| SuperDrug ATC ID |
A03AB03
|
||||
| SuperDrug CAS ID |
cas=014214847
|
||||
| Target and Pathway | |||||
| Target(s) | Muscarinic acetylcholine receptor M1 | Target Info | Antagonist | [2] | |
| KEGG Pathway | Calcium signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| PI3K-Akt signaling pathway | |||||
| Cholinergic synapse | |||||
| Regulation of actin cytoskeleton | |||||
| PANTHER Pathway | Alzheimer disease-amyloid secretase pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Muscarinic acetylcholine receptor 1 and 3 signaling pathway | |||||
| Reactome | Muscarinic acetylcholine receptors | ||||
| G alpha (q) signalling events | |||||
| WikiPathways | Monoamine GPCRs | ||||
| Calcium Regulation in the Cardiac Cell | |||||
| Regulation of Actin Cytoskeleton | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Gastrin-CREB signalling pathway via PKC and MAPK | |||||
| Secretion of Hydrochloric Acid in Parietal Cells | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015 | ||||
| REF 2 | Ultraviolet spectroscopic estimation of microenvironments and bitter tastes of oxyphenonium bromide in cyclodextrin solutions. J Pharm Sci. 1999 Aug;88(8):759-62. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.